United Therapeutics

UNITED THERAPEUTICS CORP

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Jakarta,-,August,15,2024:,Applovin,Corporation,Logo,Signboard.,Is,An

Large Cap

News

Movers

Trading Ideas

CHWY

CVNA

GRAB

LULU

MBLY

UTHR

11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts.

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?

Petróleo

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CASY

CVGW

EVGN

INSM

LQDA

Dow Gains 50 Points; US Small Business Optimism Index Rises In May

biotech lab

Biotech

Health Care

General

Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

Press Releases

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

United Therapeutics Named to '100 Best Companies to Work For' in 2025 by Fortune Media and Great Place to Work

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

B of A Securities

Cantor Fitzgerald

HC Wainwright & Co.

JP Morgan

Morgan Stanley

Comments

United Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell